Ergothioneine-containing composition for preventing or improving menopausal symptoms
Patent Information
- Application Number
- MYPI2025004911
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-16
- Filing Date
- 2024-02-13
- Publication Date
- 2024-08-16
AI Technical Summary
Current treatments for menopausal symptoms, such as hormone replacement therapy, come with side effects like cancer risk, headaches, and weight gain, necessitating a safer alternative for daily consumption as food or drink.
A composition containing L-ergothioneine or its salt, which inhibits ATP-sensitive potassium channels and phosphodiesterase 5 and 7A1, addressing symptoms like muscle pain, erectile dysfunction, hair loss, and urinary disorders, and is formulated as an oral food or drink.
The composition effectively prevents or improves menopausal symptoms by enhancing blood flow, reducing inflammation, and promoting hair growth, with minimal side effects due to its natural origin and safe long-term ingestion.
Smart Images

Figure PI2025004911_DRAWING_001
Abstract
Description
Composition containing ergothioneine for preventing or ameliorating menopausal symptoms
[0001] The present invention relates to a composition containing ergothioneine for preventing or ameliorating menopausal symptoms, etc.
[0002] Menopausal symptoms are caused by a decrease in the secretion of male or female hormones. In women, the decrease in estrogen secretion due to ovarian aging causes symptoms such as high fever, sweating, insomnia, depression, urinary incontinence, hair loss, muscle pain, and osteoporosis, which appear approximately 2 to 10 years before and after menopause. In men, a decrease in blood testosterone causes symptoms such as erectile dysfunction, decreased libido, urinary problems, and abnormal blood cholesterol metabolism, in addition to the above symptoms.
[0003] Hormone replacement therapy and non-steroidal preparations have been developed to prevent and treat these menopausal symptoms, and hormone replacement therapy is currently the most effective method. However, long-term administration of hormones can cause side effects such as cancer risk, headaches, and weight gain. There is an urgent need for safer ingredients that can prevent or improve menopausal symptoms and can be taken daily as foods and beverages.
[0004] Ergothioneine is an amino acid found in mushrooms and the like, and naturally exists in the L-form. Patent Document 1 discloses that applying an extract of mushroom fruiting bodies containing ergothioneine, niacin, and pantothenic acid to the top of the head has been confirmed to have a hair-thickening effect.
[0005] Japanese Patent Application Laid-Open No. 2009-275027
[0006] However, Patent Document 1 does not describe at all the hair-growing effect of ergothioneine alone or its influence on menopausal symptoms.
[0007] An object of the present invention is to provide a composition for preventing or ameliorating menopausal symptoms.
[0008] As a result of intensive research conducted by the present inventors to solve the above problems, they have found that L-ergothioneine or a salt thereof has the effect of preventing or ameliorating menopausal symptoms.
[0009] That is, the present invention relates to, but is not limited to, the following compositions for preventing or ameliorating menopausal symptoms: [1] A composition for preventing or ameliorating menopausal symptoms, comprising ergothioneine or a salt thereof as an active ingredient. [2] The composition according to [1] above, wherein the menopausal symptoms are at least one symptom selected from the group consisting of muscle pain, erectile dysfunction, urogenital dysfunction, decreased hair quantity and / or quality, and decreased sexual energy. [3] The composition according to [1] or [2] above, wherein the menopausal symptoms are andropause symptoms. [4] The composition according to any of [1] to [3] above, which prevents or ameliorate menopausal symptoms via an ATP-sensitive potassium channel. [5] The composition according to any of [1] to [4] above, which inhibits phosphodiesterase 5 or phosphodiesterase 7A1. [6] The composition according to any of [1] to [5] above, which is an oral composition. [7] The composition according to any of [1] to [6] above, which is a food or drink. [8] The composition according to any one of [1] to [7] above, which is labeled with at least one function selected from the group consisting of "preventing menopausal symptoms," "ameliorating menopausal symptoms," "supporting hormone deficiency in middle-aged and elderly people," "improving reproductive function in middle-aged and elderly people," "ameliorating urinary disorders in middle-aged and elderly people," "preventing hair loss in middle-aged and elderly people," "ameliorating hair loss in middle-aged and elderly people," and "ameliorating decreased sexual energy in middle-aged and elderly people." [9] A method for preventing or ameliorating menopausal symptoms, which comprises administering ergothioneine or a salt thereof to a subject.
[10] Use of ergothioneine or a salt thereof for preventing or ameliorating menopausal symptoms.
[0010] According to the present invention, a composition for preventing or ameliorating menopausal symptoms can be provided.
[0011] Figure 1 is a graph evaluating the inhibitory activity of L-ergothioneine against phosphodiesterase 5. Figure 2 is a graph evaluating the inhibitory activity of L-ergothioneine against phosphodiesterase 7A1. Figure 3 is a graph evaluating the inhibitory activity of L-ergothioneine against substrate binding to ATP-sensitive potassium channels.
[0012] The composition for preventing or ameliorating menopausal symptoms of the present invention contains ergothioneine or a salt thereof as an active ingredient. Hereinafter, the composition for preventing or ameliorating menopausal symptoms of the present invention will also be referred to as the "composition of the present invention." Ergothioneine is a type of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine. The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for use in foods and beverages, and may be either an acidic salt or a basic salt. Examples of acidic salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; and organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, and propionate. Examples of basic salts include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt and magnesium salt.
[0013] Ergothioneine or a salt thereof is not limited in any way by its form, production method, etc. Ergothioneine or a salt thereof may be a chemically synthesized product, or may be extracted and purified from a natural product. L-ergothioneine is contained in large amounts in the Golden / Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), a mushroom of the Pleurotus genus in the family Pleurotus. L-ergothioneine is found in mushrooms such as white button mushrooms, crimini mushrooms, and portabella mushrooms (Agaricus bisporus), Grey Oyster Mushrooms (Pleurotus ostreatus), shiitake mushrooms (Lentinula edodes), Maitake mushrooms (Grifola frondosa), reishi mushrooms (Ganoderma lucidum), Yamabushitake mushrooms (Hericium erinaceus), Yanagimatsutake mushrooms (Agrocybe aegerita), and chanterelle mushrooms (Cantharella verruca). It is also contained in mushrooms such as mushrooms such as Pleurotus cibarius, porcini mushroom (scientific name: Boletus edulis), and morel mushroom (scientific name: Morchella esculenta). When obtaining L-ergothioneine from a natural product, it is preferably extracted from Pleurotus cornucopiae. Ergothioneine or a salt thereof can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.
[0014] L-ergothioneine or a salt thereof is a compound that is contained in natural products and foods and beverages and has been consumed as a dietary source. Therefore, from the viewpoint of safety, ergothioneine or a salt thereof is considered to pose few problems, even when taken over a long period of time. According to the present invention, a highly safe composition for preventing or ameliorating menopausal symptoms can be provided.
[0015] Menopausal symptoms are induced by a decrease in the secretion of male or female hormones, and the symptoms are diverse. Therefore, a composition for preventing or ameliorating menopausal symptoms that exhibits multiple effects is desirable. The menopausal symptoms are preferably at least one symptom selected from the group consisting of muscle pain, erectile dysfunction, urogenital dysfunction, decreased hair quantity and / or quality, and decreased sexual energy. Examples of urogenital dysfunction include dysuria. Decreased sexual energy refers to a decline in mental and physical activity. In the present invention, the menopausal symptoms may be male menopausal symptoms or female menopausal symptoms, but are preferably male menopausal symptoms. Examples of male menopausal symptoms include, but are not limited to, the symptoms exemplified above.
[0016] As shown in the Examples below, L-ergothioneine has the effect of inhibiting substrate binding to ATP-sensitive potassium (K ATP) channels. Furthermore, L-ergothioneine has the effect of inhibiting phosphodiesterase 5 (PDE5) and phosphodiesterase 7A1 (PDE7A1). It is known that opening of vascular smooth muscle ATP-sensitive potassium channels improves blood flow in hair tissue. It is also known that opening of mitochondrial ATP-sensitive potassium channels suppresses apoptosis of hair matrix cells. It is also known that opening of ATP-sensitive potassium channels promotes proliferation of dermal papilla cells. Therefore, ergothioneine or a salt thereof can improve loss of hair volume and / or quality via K ATP channels.
[0017] Furthermore, when PDE5 is inhibited, the degradation of cGMP, which is involved in the relaxation of vascular smooth muscle, is suppressed, resulting in effects such as vasodilation and smooth muscle relaxation. This effect is known to increase blood flow and oxygen supply, improving dysuria in prostatic hyperplasia and erectile dysfunction. Furthermore, when PDE5 is inhibited, muscle damage after treadmill training is reduced in mice, improving endurance performance (J Appl Physiol (1985), 2019 Jun 1; 126(6): 1737-1745). As described above, inhibition of PDE5 can prevent or improve erectile dysfunction, urogenital dysfunction, and sexual dysfunction. Ergothioneine or a salt thereof can prevent or improve erectile dysfunction, urogenital dysfunction, and sexual dysfunction by inhibiting PDE5.
[0018] It is also known that inhibition of PDE7A1 suppresses cytokine production and exerts an anti-inflammatory effect. It is also known that inhibition of substrate binding to K ATP channels opens K ATP channels and causes vasodilation. Suppression of inflammation prevents or alleviates muscle pain. It is also thought that vasodilation improves blood flow and prevents or alleviates muscle pain. Therefore, ergothioneine or a salt thereof can prevent or alleviate muscle pain by inhibiting PDE7A1 and / or acting via the K ATP channel.
[0019] The composition of the present invention is used to prevent or ameliorate menopausal symptoms. Preventing symptoms includes preventing onset, delaying onset, reducing the incidence, reducing the risk of onset, etc. Ameliorating symptoms includes recovering a subject from the symptoms, alleviating symptoms, improving symptoms, delaying or preventing the progression of symptoms, etc. Amelioration includes partial recovery.
[0020] The composition of the present invention may be either an oral composition or a parenteral composition, but is preferably an oral composition. Specific examples of oral compositions include foods and beverages, oral medicines, quasi-drugs, etc., and are preferably foods and beverages or oral medicines, more preferably foods and beverages. The composition of the present invention may be a material or preparation to be incorporated into foods and beverages, medicines, quasi-drugs, etc.
[0021] The compositions of the present invention can be used for either therapeutic (medical) or non-therapeutic (non-medical) purposes, the latter being a concept that does not include medical procedures, i.e., human surgery, treatment, or diagnosis.
[0022] The composition of the present invention may contain any additives and any components in addition to ergothioneine or a salt thereof, as long as the effects of the present invention are not impaired. These additives and components can be selected depending on the form of the composition, etc. When the composition of the present invention is an oral composition, additives that can generally be used in oral compositions such as foods and beverages, pharmaceuticals, and quasi-drugs can be used.
[0023] When the composition of the present invention is made into a food or drink, a pharmaceutical product, a quasi-drug, etc., the method for producing it is not particularly limited, and it can be produced by a general method. The form of the oral composition of the present invention is not particularly limited, and it may be a solid (powder, granules, tablet, etc.), a liquid, a paste, etc.
[0024] For example, when the composition of the present invention is made into a food or beverage, various foods and beverages can be prepared by blending ergothioneine or a salt thereof with ingredients that can be used in foods and beverages (e.g., food ingredients, food additives used as needed, etc.). The foods and beverages are not particularly limited, and examples include general foods and beverages, health foods, health supplements, health drinks, functional foods, foods for specified health uses, and foods and beverages for patients. The health foods, health supplements, functional foods, foods for specified health uses, etc. can be used in various dosage forms, such as fine granules, tablets, granules, powders, capsules, chewable tablets, dry syrups, syrups, liquids, beverages, drinks, and liquid diets.
[0025] When the composition of the present invention is used as a pharmaceutical or quasi-drug, it can be formulated into various dosage forms by blending ergothioneine or a salt thereof with a pharmacologically acceptable carrier and, if necessary, additives. Such carriers, additives, etc. may be any pharmacologically acceptable carriers that can be used in pharmaceuticals or quasi-drugs, and examples thereof include one or more of excipients, binders, disintegrants, lubricants, antioxidants, colorants, etc. The pharmaceutical or quasi-drug may be administered orally or parenterally (transdermally, transmucosally, enterally, by injection, etc.). When the composition of the present invention is used as a pharmaceutical or quasi-drug, it is preferably an oral pharmaceutical or oral quasi-drug. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewable tablets, etc. Dosage forms for parenteral administration include, for example, injections, drip infusions, ointments, lotions, patches, suppositories, nasal preparations, and pulmonary preparations (inhalants).
[0026] The subject to which the composition of the present invention is ingested or administered (which can also be referred to as the administration subject) is not particularly limited. It is preferably a human. In one embodiment, the administration subject includes a subject who requires or desires prevention or amelioration of menopausal symptoms. Examples of such subjects include middle-aged and elderly people. In one embodiment, the composition of the present invention is suitably used as a composition for preventing or ameliorating menopausal symptoms in middle-aged and elderly people. Middle-aged and elderly people include elderly people. Elderly people may be, for example, people aged 60 or older or 65 or older. Middle-aged and elderly people may be, for example, people aged 40 or older. In one embodiment, among middle-aged and elderly people, subjects aged 40 or older and 70 or younger are preferred. The administration subject may be a healthy individual. The composition of the present invention can also be used in healthy individuals, for example, for the purpose of preventing or ameliorating menopausal symptoms. In the present invention, a particularly preferred subject is a healthy individual aged 45 or older and 65 or younger.
[0027] The content of ergothioneine or a salt thereof in the composition of the present invention is not particularly limited and can be set depending on the form, etc. The content of ergothioneine or a salt thereof in the composition of the present invention, calculated as ergothioneine, is, for example, preferably 0.0001% by weight or more, more preferably 0.001% by weight or more, and preferably 90% by weight or less, more preferably 50% by weight or less. In one aspect, the content of ergothioneine or a salt thereof in the composition of the present invention, calculated as ergothioneine, is preferably 0.0001 to 90% by weight, more preferably 0.001 to 50% by weight. The content of ergothioneine or a salt thereof can be measured by high-performance liquid chromatography (HPLC).
[0028] In this specification, the expression "ergothioneine equivalent amount" or similar expressions means the amount of ergothioneine, and in the case of a salt of ergothioneine, means the value obtained by multiplying the number of moles of the salt by the molecular weight of ergothioneine.
[0029] The composition of the present invention can be ingested or administered by an appropriate method depending on its form. In one embodiment, the composition of the present invention is preferably ingested orally (orally administered). The dosage (also referred to as intake amount) of the composition of the present invention is not particularly limited, and may be an amount that can provide an effect of preventing or improving menopausal symptoms, and may be appropriately determined depending on the dosage form, administration method, subject weight, etc.
[0030] In one embodiment, when the composition of the present invention is orally ingested or administered to a human (adult), the dosage is preferably 2 mg or more, more preferably 5 mg or more, even more preferably 7 mg or more, and preferably 50 mg or less, more preferably 25 mg or less, and even more preferably 20 mg or less per day, in terms of ergothioneine or a salt thereof (ergothioneine equivalent). In one embodiment, the dosage of the composition of the present invention is preferably 2 to 50 mg, more preferably 5 to 25 mg, even more preferably 5 to 20 mg, and even more preferably 7 to 20 mg per day, in terms of ergothioneine or a salt thereof (ergothioneine equivalent). It is preferable that the above amount be ingested or administered once or more times a day, for example, once a day or in divided doses (e.g., 2 to 3 times a day). In one embodiment, the above amount of ergothioneine or a salt thereof is orally ingested or administered to a human. The above dosage may be per 60 kg of body weight. In one embodiment, the composition of the present invention can be used to ingest or administer the above-mentioned amount of ergothioneine or a salt thereof per 60 kg of body weight per day to a human.
[0031] The content of ergothioneine or a salt thereof in the composition of the present invention is preferably 2 to 50 mg, more preferably 5 to 25 mg, even more preferably 5 to 20 mg, and particularly preferably 7 to 20 mg, of ergothioneine per daily intake for an adult.
[0032] The composition of the present invention may be labeled with, for example, a function indicating that it has an effect of preventing or improving menopausal symptoms, or a function exhibited by such an effect. Examples of such labels include, for example, preventing or improving muscle pain; preventing or improving erectile dysfunction; preventing or improving urogenital dysfunction; preventing or improving hair volume and / or quality loss; and preventing or improving sexual decline. The composition of the present invention may be labeled with at least one function selected from the group consisting of "preventing menopausal symptoms," "improving menopausal symptoms," "supporting hormone deficiency in middle-aged and elderly people," "improving reproductive function in middle-aged and elderly people," "improving urinary disorders in middle-aged and elderly people," "preventing hair loss in middle-aged and elderly people," "improving hair loss in middle-aged and elderly people," and "improving sexual decline in middle-aged and elderly people." In one embodiment, the composition of the present invention is preferably a food or beverage labeled with the above-mentioned label. The label may also indicate that the product is used to achieve the above-mentioned function. The label may be attached to the composition itself, or to the container or packaging of the composition.
[0033] As described above, ergothioneine or a salt thereof inhibits substrate binding to a K ATP channel. Therefore, ergothioneine or a salt thereof can also be used as an active ingredient for inhibiting substrate binding to a K ATP channel. A composition for inhibiting substrate binding to a K ATP channel, which contains ergothioneine or a salt thereof as an active ingredient, also constitutes the present invention. Furthermore, ergothioneine or a salt thereof inhibits phosphodiesterase 5 or phosphodiesterase 7A1. Therefore, ergothioneine or a salt thereof can also be used as an active ingredient for inhibiting phosphodiesterase 5 or phosphodiesterase 7A1. A composition for inhibiting phosphodiesterase 5, which contains ergothioneine or a salt thereof as an active ingredient, also constitutes the present invention. A composition for inhibiting phosphodiesterase 7A1, which contains ergothioneine or a salt thereof as an active ingredient, also constitutes the present invention.
[0034] The present invention also encompasses the following method: a method for preventing or ameliorating menopausal symptoms, which comprises administering ergothioneine or a salt thereof to a subject. The method may be a therapeutic method or a non-therapeutic method.
[0035] The present invention also encompasses the following uses: Use of ergothioneine or a salt thereof for preventing or ameliorating menopausal symptoms. The above use may be therapeutic or non-therapeutic. By administering ergothioneine or a salt thereof to a subject, it is possible to prevent or ameliorate menopausal symptoms.
[0036] In the above-mentioned methods and uses, the preferred embodiment of ergothioneine or a salt thereof is the same as that of the composition of the present invention described above. As ergothioneine or a salt thereof, one type of ergothioneine or a salt thereof may be used, or two or more types may be used. In the above-mentioned methods and uses, it is preferable to administer (ingest) ergothioneine or a salt thereof to a subject at least once a day, for example, once to several times (e.g., two to three times) a day. In the above-mentioned methods and uses, it is preferable to orally administer (ingest) ergothioneine or a salt thereof. The above-mentioned uses are preferably used in humans.
[0037] In the above-mentioned methods and uses, ergothioneine or a salt thereof may be used in an amount sufficient to achieve the desired effect (which may also be referred to as an effective amount). The preferred dosage and administration targets of ergothioneine or a salt thereof are the same as those of the above-mentioned composition of the present invention. Ergothioneine or a salt thereof may be administered directly or as a composition containing it. For example, the above-mentioned composition of the present invention may be used.
[0038] The present invention also encompasses use of ergothioneine or a salt thereof for producing a composition for preventing or ameliorating menopausal symptoms. The present invention also relates to ergothioneine or a salt thereof for use in preventing or ameliorating menopausal symptoms.
[0039] In this specification, a numerical range expressed by a lower limit and an upper limit, i.e., "lower limit to upper limit," includes the lower limit and the upper limit. For example, a range expressed by "1 to 2" means 1 or more and 2 or less, including 1 and 2. In this specification, the upper limit and the lower limit may be any combination of ranges.
[0040] The present invention will be described in more detail below with reference to examples, but the scope of the present invention is not limited to these examples.
[0041] Example 1 Evaluation of Inhibitory Activity of Phosphodiesterase To evaluate the molecular target of L-ergothioneine, in vitro assays were carried out against phosphodiesterase 5 (PDE5) and phosphodiesterase 7A1 (PDE7A1). The in vitro assays were conducted under contract to Eurofins Panlabs. The tests were carried out by the following method.
[0042] (PDE5) PDE5 isolated from human platelets (Eurofins Cerep) was used. 60 ng of PDE5 was dissolved in 44 mM Tris / HCl (pH 7.4), 3 mM MgCl 2 , 1.04 mM dithiothreitol (DTT), 0.03% bovine serum albumin (BSA), 2% glycerol, 200 mM NH 4 Cl and 0.1 μM Ci[ 3 The samples were incubated with L-ergothioneine (L-ergothioneine concentration: 100 μM or 1000 μM) in a buffer containing [H]cGMP at 22° C. for 30 minutes. After adding Phosphodiesterase SPA beads (product number: RPNQ0150, manufactured by PerkinElmer), luminescence was detected with a detector. 3 The inhibitory activity of L-ergothioneine was evaluated using the amount of [H]5'GMP as an index. 3 The amount of 5' GMP in the reaction mixture to which L-ergothioneine was added was taken as 100% PDE5 activity. 3The PDE5 activity (%) relative to the control was calculated from the amount of [H]5'GMP. The inhibitory activity (%) was calculated using the following formula: Inhibitory activity (%) = 100 - (PDE5 relative activity when L-ergothioneine was added)
[0043] (PDE7A1) Human recombinant PDE7A1 (Eurofins Cerep) expressed in insect cells was used. 0.6 U of PDE7A1 was dissolved in 40 mM Tris / HCl (pH 7.4), 8 mM MgCl 2 and 0.035 μM Ci[ 3 The mixture was incubated with L-ergothioneine (L-ergothioneine concentrations: 100 μM and 1000 μM) in a buffer containing [H]cAMP at 22° C. for 30 minutes. After adding Phosphodiesterase SPA beads (product number: RPNQ0150, manufactured by PerkinElmer), luminescence was detected with a detector. 3 The inhibitory activity of L-ergothioneine was evaluated using the amount of [H]5'AMP as an index. 3 The amount of [H]5'AMP in the reaction mixture to which L-ergothioneine was added was taken as 100% PDE7A1 activity. 3 The relative PDE7A1 activity (%) to the control was calculated from the amount of [H]5'AMP. The inhibitory activity (%) was calculated using the following formula: Inhibitory activity (%) = 100 - (relative PDE7A1 activity when L-ergothioneine was added)
[0044] FIG. 1 is a graph evaluating the inhibitory activity of L-ergothioneine against phosphodiesterase 5. FIG. 2 is a graph evaluating the inhibitory activity of L-ergothioneine against phosphodiesterase 7A1. The concentration (μM) on the horizontal axis in FIGS. 1 and 2 represents the concentration of L-ergothioneine. L-ergothioneine exhibited inhibitory activity against PDE5 and PDE7A1. PDE5 is known to increase blood flow and oxygen supply through vasodilatory and smooth muscle relaxation effects, and to improve urogenital dysfunction such as dysuria due to benign prostatic hyperplasia, as well as erectile dysfunction. Inhibition of PDE5 is also known to improve stamina, suggesting a preventive or ameliorative effect against menopausal sexual decline. Inhibition of PDE7A1 is also known to suppress cytokine production, exerting an anti-inflammatory effect and preventing or ameliorating muscle pain. Therefore, it is presumed that L-ergothioneine exhibits the above-mentioned effects by inhibiting PDE5 and PDE7A1.
[0045] Example 2 (Evaluation of substrate binding inhibitory activity on ATP-sensitive potassium channels) To evaluate the molecular target on which L-ergothioneine acts, an in vitro assay was carried out on the ATP-sensitive potassium (KATP) channel. The in vitro assay was carried out as a contract test at Eurofins Panlabs. The test was carried out by the following method.
[0046] 400 μg of membrane fraction from rat cerebral cortex (containing K ATP channels; Eurofins Cerep) was diluted with 0.1 nM [ 3 The cells were incubated with [H] glibenclamide and L-ergothioneine (L-ergothioneine concentration: 100 μM or 1000 μM) at 22°C for 60 minutes. Glibenclamide is a K ATP channel inhibitor. Nonspecific binding was determined in the presence of 1 μM glibenclamide (no L-ergothioneine). When glibenclamide was present in excess, [ 3Since [H]glibenclamide is no longer able to bind to the K ATP channel, the radioactivity detected there is nonspecific binding. The membrane fraction was filtered and washed, and the substrate binding inhibitory activity of L-ergothioneine was evaluated using radioactivity as an indicator. [H]glibenclamide bound to the K ATP channel 3 The higher the amount of [H]glibenclamide, the stronger the radioactivity of the membrane fraction.
[0047] FIG. 3 is a graph evaluating the substrate binding inhibitory activity of L-ergothioneine on ATP-sensitive potassium channels. The concentration (μM) on the horizontal axis represents the concentration of L-ergothioneine. The substrate binding inhibitory activity (%) on K ATP channels was determined by the following procedure. The radioactivity of the membrane fraction in the reaction solution without L-ergothioneine (control) was set to 100%, and the relative activity (%) of the membrane fraction in the reaction solution containing L-ergothioneine (100 μM or 1000 μM) relative to the control was calculated from the radioactivity of the membrane fraction. When L-ergothioneine inhibits the binding of glibenclamide to K ATP channels, the radioactivity of the membrane fraction is weakened. The substrate binding inhibitory activity (%) on K ATP channels was then calculated by subtracting the relative activity (%) of the membrane fraction in the control (100%).
[0048] L-ergothioneine exhibited inhibitory activity against the binding of its substrate, glivenclamide, to ATP-sensitive potassium channels. It is known that opening of vascular smooth muscle ATP-sensitive potassium channels improves blood flow in hair tissue. It is also known that opening of mitochondrial ATP-sensitive potassium channels suppresses apoptosis of hair matrix cells. It is also known that opening of ATP-sensitive potassium channels promotes proliferation of dermal papilla cells. Therefore, it is presumed that L-ergothioneine improves the loss of hair volume and / or quality via ATP-sensitive potassium channels. It is also known that inhibition of substrate binding to K ATP channels opens K ATP channels and dilates blood vessels. It is thought that dilation of blood vessels improves blood flow and prevents or improves muscle pain. Therefore, it is presumed that L-ergothioneine prevents or improves muscle pain via ATP-sensitive potassium channels.
Claims
1. A composition for preventing or ameliorating menopausal symptoms, comprising ergothioneine or a salt thereof as an active ingredient.
2. The composition according to claim 1, wherein the menopausal symptoms are at least one symptom selected from the group consisting of muscle pain, erectile dysfunction, decreased urogenital function, decreased hair volume and / or quality, and decreased sexual desire.
3. The composition according to claim 1 or 2, wherein the menopausal symptoms are male menopausal symptoms.
4. The composition according to claim 1 or 2, which prevents or improves menopausal symptoms via ATP-sensitive potassium channels.
5. The composition of claim 1 or 2, which inhibits phosphodiesterase 5 or phosphodiesterase 7A1.
6. The composition according to claim 1 or 2, which is an oral composition.
7. The composition according to claim 6, which is a food or drink.
8. The composition according to claim 1 or 2, which is labeled with at least one function selected from the group consisting of "preventing menopausal symptoms", "ameliorating menopausal symptoms", "supporting hormone deficiency in middle-aged and elderly people", "improving reproductive function in middle-aged and elderly people", "ameliorating urinary disorders in middle-aged and elderly people", "preventing hair loss in middle-aged and elderly people", "ameliorating hair loss in middle-aged and elderly people" and "ameliorating decreased sexual energy in middle-aged and elderly people".
9. A method for preventing or ameliorating menopausal symptoms, which comprises administering ergothioneine or a salt thereof to a subject.
10. Use of ergothioneine or a salt thereof for preventing or ameliorating menopausal symptoms.
